EXPLAINED: Provention bio | Rare Historical Photos

Lisa Jarvis: A diabetes breakthrough in search of patients

In a first, the U.S. Food and Drug Administration has approved a therapy that slows the onset of Type 1 diabetes. Teplizumab, developed by Provention Bio, typically delays the need for insulin shots, blood-sugar monitoring, and diet control by about two years. For some, the effect lasted years longer.

Tribune News Service · Nov 29, 2022

Why Aehr Test Systems Shares Are Trading Higher By Over 19%, Here Are 51 Stocks Moving In Friday's Mid-Day Session

Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) jumped 108% to $3.3943 on abnormally-high volume. The company released its October investor presentation yesterday.

Benzinga · Oct 7, 2022

Dow Drops Over 400 Points After US Economy Adds 263,000 Jobs During September

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 400 points on Friday.

Benzinga · Oct 7, 2022

Provention Bio Earnings Conference Call Is Coming Up, Here's What You Need To Know

Provention Bio (NASDAQ:PRVB) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Provention Bio (PRVB) Conference Call Follow this link to access the live webcast.

Benzinga · Apr 28, 2022

The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Jan 28, 2022